P
HRMY icon

Paradiem’s Harmony Biosciences HRMY Stock Holding History

Paradiem’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
40,854
+32,470
+387% +$1.02M 0.32% 48
2026
Q1 		$235K Sell
8,384
-17,792
-68% -$583K 0.05% 69
2025
Q4 		$980K Sell
26,176
-103
-0.4% -$3.39K 0.23% 46
2025
Q3 		$724K Buy
+26,279
New +$905K 0.17% 63
2024
Q2 		– Sell
-93,930
Closed -$3.15M – 96
2024
Q1 		$3.15M Sell
93,930
-13,101
-12% -$420K 0.78% 57
2023
Q4 		$3.46M Buy
107,031
+29,847
+39% +$833K 0.96% 48
2023
Q3 		$2.53M Buy
77,184
+17,650
+30% +$613K 0.76% 65
2023
Q2 		$2.1M Sell
59,534
-7,461
-11% -$258K 0.6% 72
2023
Q1 		$2.19M Buy
66,995
+11,458
+21% +$522K 0.68% 72
2022
Q4 		$3.06M Buy
55,537
+3,405
+7% +$187K 1.13% 44
2022
Q3 		$2.31M Buy
+52,132
New +$2.54M 0.89% 66

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paradiem's HRMY Position: Q2 2026 in Review

Paradiem increased its Harmony Biosciences (HRMY) stake by 387% in Q2 2026, buying an estimated $1.02M and bringing the position to 40,854 shares worth $1.49M. The position accounts for 0.32% of the portfolio, ranked #48.

Paradiem first reported a position in HRMY in Q3 2022 and has held it in 11 quarters since. The position peaked at $3.46M in Q4 2023. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Paradiem held 40,854 shares of Harmony Biosciences worth $1.49M as of Q2 2026.
  • Paradiem bought 32,470 Harmony Biosciences shares in Q2 2026, an estimated $1.02M.
  • Harmony Biosciences made up 0.32% of Paradiem's portfolio in Q2 2026, its #48 holding.
  • Paradiem first reported a position in Harmony Biosciences in Q3 2022 and has held it in 11 quarters since.
  • Paradiem's Harmony Biosciences position peaked at $3.46M in Q4 2023.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Paradiem's 13F filing for Q2 2026, filed 14 Jul 2026.